Directed evolution of adeno-associated virus to an infectious respiratory virus

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 10, 2009, Pages 3865-3870

  Excoffon, Katherine J D A ^a   Koerber, James T ^b   Dickey, David D ^a   Murtha, Matthew ^c   Keshavjee, Shaf ^d   Kaspar, Brian K ^c   Zabner, Joseph ^a   Schaffer, David V ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR; PHOSPHOLIPASE A2; SIALIC ACID; SIALIDASE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; CELL SPECIFICITY; CHLORIDE TRANSPORT; CONTROLLED STUDY; CYSTIC FIBROSIS; DIRECTED MOLECULAR EVOLUTION; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO SELECTION; MOLECULAR MODEL; MUTATION; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; RESPIRATORY VIRUS; VIRAL GENE THERAPY; VIRUS ATTACHMENT; VIRUS INFECTIVITY;

ANIMALS; CAPSID; CELL LINE; CELL POLARITY; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDOVIRUS; DIRECTED MOLECULAR EVOLUTION; EPITHELIAL CELLS; GENE LIBRARY; GENETIC VECTORS; HUMANS; MODELS, MOLECULAR; MUTATION; N-ACETYLNEURAMINIC ACID; PARVOVIRIDAE INFECTIONS; PHENOTYPE; SELECTION (GENETICS); TRANSDUCTION, GENETIC; VIRUS ATTACHMENT;

ADENO-ASSOCIATED VIRUS;

EID: 62649174755     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0813365106     Document Type: Article

References (54)

1. Boots M, Mealor M (2007) Local interactions select for lower pathogen infectivity. Science 315:1284-1286.
2. Mills CE, Robins JM, Lipsitch M (2004) Transmissibility of 1918 pandemic influenza. Nature 432:904-906.
3. Flotte TR, et al. (2007) Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis. Mol Ther 15:229-241.
4. Wang G, et al. (1999) Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J Clin Invest 104:R55-62.
5. Johnson LG, Olsen JC, Naldini L, Boucher RC (2000) Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo. Gene Ther 7:568-574.
6. Zabner J, et al. (1997) Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. J Clin Invest 100:1144-1149.
7. Zhao H, et al. (1998) Molecular evolution by staggered extension process (StEP) in vitro recombination. Nat Biotechnol 16:258-261.
8. Stemmer WP (1994) DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution. Proc Natl Acad Sci USA 91:10747-10751.
9. Isaacs FJ, Dwyer DJ, Collins JJ (2006) RNA synthetic biology. Nat Biotechnol 24:545-554.
10. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV (2006) Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 24:198-204.
11. Sarkar I, Hauber I, Hauber J, Buchholz F (2007) HIV-1 proviral DNA excision using an evolved recombinase. Science 316:1912-1915.
12. Muzyczka N, Berns KI (2001) in Fields Virology, eds Knipe DM and Howley PM (Lippincott, Williams & Wilkins, Philadelphia), pp. 2327-2359.
13. Summerford C, Samulski RJ (1998) Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72:1438-1445.
14. Asokan A, et al. (2006) Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. J Virol 80:8961-8969.
15. Walters RW, et al. (2001) Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 276:20610-20616.
16. Di Pasquale G, et al. (2003) Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9:1306-1312.
17. Gao G, et al. (2004) Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 78:6381-6388.
18. Duffy S, Shackelton LA, Holmes EC (2008) Rates of evolutionary change in viruses: Patterns and determinants. Nature Rev Genet 9:267-276.
19. Wagner JA, et al. (1998) A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Hum Gene Ther 9:889-909.
20. Moss RB, et al. (2007) Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: A randomized placebo-controlled phase 2B trial. Hum Gene Ther 18:726-732.
21. Hauswirth W, et al. (2008) Phase I trial of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results. Hum Gene Ther, 10.1089/hgt.2008.107.
22. Pickles RJ (2004) Physical and biological barriers to viral vector-mediated delivery of genes to the airway epithelium. Proc Am Thor Soc 1:302-308.
23. Koerber JT, Jang J-H, Schaffer DV (2008) DNA shuffling of Adeno-associated Virus Yields Functionally Diverse Viral Progeny. Mol Ther 16:1703-1709.
24. Nam HJ, et al. (2006) Identification of the sialic acid structures recognized by minute virus of mice and the role of binding affinity in virulence adaptation. J Biol Chem 281:25670-25677.
25. Canaan S, et al. (2004) Interfacial enzymology of parvovirus phospholipases A2. J Biol Chem 279:14502-14508.
26. Ostedgaard LS, et al. (2005)Ashortened adeno-associated virus expression cassette for CFTR gene transfer to cystic fibrosis airway epithelia. Proc Natl Acad Sci USA 102:2952-2957.
27. Ostedgaard LS, et al. (2002) CFTR with a partially deleted R domain corrects the cystic fibrosis chloride transport defect in human airway epithelia in vitro and in mouse nasal mucosa in vivo. Proc Natl Acad Sci USA 99:3093-3098.
28. Zadori Z, et al. (2001) A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 1:291-302.
29. Takeuchi Y, Myers R, Danos O (2008) Recombination and population mosaic of a multifunctional viral gene, adeno-associated virus cap. PLoS ONE 3:e1634.
30. Urabe M, et al. (2006) Scalable generation of high-titer recombinant adeno-associated virus type 5 in insect cells. J Virol 80:1874-1885.
31. Kohlbrenner E, et al. (2005) Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol Ther 12:1217-1225.
32. Yan Z, et al. (2004) Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia. J Virol 78:2863-2874.
33. Liu CK, Hope AP, Atwood WJ (1998) The human polyomavirus, JCV, does not share receptor specificity with SV40 on human glial cells. J Neurovirol 4:49-58.
34. Vlasak R, Luytjes W, Spaan W, Palese P (1988) Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses. Proc Natl Acad Sci USA 85:4526-4529.
35. Tumpey TM, et al. (2007) A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science 315:655-659.
36. Chandrasekaran A, et al. (2008) Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nature Biotech 26:107-113.
37. Govindasamy L, et al. (2006) Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J Virol 80:11556-11570.
38. Walters RW, et al. (2004) Structure of adeno-associated virus serotype 5. J Virol 78:3361-3371.
39. Nam HJ, et al. (2007) Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol 81:12260-12271.
40. Xie Q, et al. (2002) The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA 99:10405-10410.
41. Grimm D, et al. (2008) In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 82:5887-5911.
42. Li W, et al. (2008) Engineering and selection of shuffled AAV genomes: A new strategy for producing targeted biological nanoparticles. Mol Ther 16:1252-1260.
43. Muller OJ, et al. (2003) Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 21:1040-1046.
44. Girod A, et al. (1999) Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 5:1052-1056.
45. Johnson LG, et al. (1992) Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 2:21-25.
46. Salinas D, et al. (2005) Submucosal gland dysfunction as a primary defect in cystic fibrosis. Faseb J 19:431-433.
47. Welsh MJ, et al. (1994) Cystic fibrosis gene therapy using an adenovirus vector: In vivo safety and efficacy in nasal epithelium. Hum Gene Ther 5:209-219.
48. Wilson JM, et al. (1994) Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: A phase I trial. Hum Gene Ther 5:501-519.
49. Boucher RC, et al. (1994) Gene therapy for cystic fibrosis using E1-deleted adenovirus: A phase I trial in the nasal cavity. Hum Gene Ther 5:615-639.
50. Zabner J, et al. (2000) Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 74:3852-3858.
51. Halbert CL, Allen JM, Miller AD (2001) Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol 75:6615-6624.
52. Limberis MP, Wilson JM (2006) Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci USA 103:12993-12998.
53. - transport in cystic fibrosis airway epithelia in vitro: Effect of promoter and administration method. Gene Ther 3:458-465.
54. Karp PH, et al. (2002) in Epithelial Cell Culture Protocols, ed Wise C (Humana Press, Inc., Totowa, NJ), pp. 115-137.